Immunotherapy for Blood Cancer — How It Works, Explained Simply

Immunotherapy for blood cancer is a group of treatments that use your own immune system to find and destroy cancer cells. Blood cancers like lymphoma, leukaemia and myeloma can hide from your immune defences. Immunotherapy helps your body see them again, or directly flags the cancer cells for attack. It is different from chemotherapy, which works by killing fast-growing cells. Immunotherapy may be given alone or with chemotherapy. It does not suit every patient, so at CION every case is reviewed by a tumour board first. A senior haemato-oncologist then explains in plain words whether it fits your situation, with no pressure to decide on the spot.

Chemotherapy works by attacking cells that divide quickly, which includes cancer cells but also some healthy cells like hair and gut lining. This is why chemo can cause hair loss and nausea. Immunotherapy works differently. It guides or boosts your immune system so it recognises and removes cancer cells more precisely. Because of this, some healthy cells may be spared. However, immunotherapy can cause its own side effects, such as fever, fatigue or immune reactions where the body inflames healthy organs. Neither treatment is better in every case. The right choice depends on your blood cancer type, biology, age and overall health. Our team explains both options honestly so you can decide with confidence.

Immunotherapy is used in several blood cancers, but not all, and not for every patient. It is commonly used in certain lymphomas, including Hodgkin and non-Hodgkin types, especially B-cell lymphomas. Some leukaemias respond to specific immunotherapies, and multiple myeloma is increasingly treated with newer antibody-based options. Whether immunotherapy will help depends on the exact subtype and whether the cancer cell carries the marker the drug must target. This is why testing is important before any decision. At CION, we confirm the precise diagnosis, order only the tests that are needed, and review your case at a tumour board. We then explain clearly whether immunotherapy is a realistic option for you.

Monoclonal antibodies are proteins made in a laboratory to copy your body's natural antibodies. They are designed to stick to a specific marker found on cancer cells, like placing a bright label on them. Once attached, the antibody can signal your immune system to attack the cell, block the cell from growing, or carry a treatment directly to it. A common example in blood cancer is rituximab, used in many B-cell lymphomas. Because the antibody targets a marker, it can be more precise than chemotherapy. However, it only works if the cancer cell carries that specific marker. Your doctor will check this with tests before recommending an antibody-based treatment.

Checkpoint inhibitors are a type of immunotherapy that release the brakes on your immune system. Cancer cells sometimes press a hidden switch on your immune cells, telling them to stand down so the cancer can grow unnoticed. Checkpoint inhibitors block this switch, allowing your immune cells to recognise and fight the cancer again. Examples include nivolumab and pembrolizumab, which are used in some cases of Hodgkin lymphoma. They do not work for every blood cancer, and they can cause immune-related side effects, where the freed immune system also inflames healthy organs. Your care team monitors you closely for this. At CION, the decision to use a checkpoint inhibitor is always reviewed by our tumour board first.

Bispecific antibodies are a newer type of immunotherapy that can grab two targets at the same time. One arm of the antibody holds onto the cancer cell, while the other arm holds onto an immune T-cell. By pulling them close together, the antibody helps your T-cell attack and kill the cancer cell. A simple picture is a handshake that forces the fighter and the target to meet. Blinatumomab is one example used in certain types of leukaemia. Bispecific antibodies can be powerful, but they need careful monitoring because the strong immune activity can cause reactions. Whether a bispecific antibody suits you depends on your exact diagnosis, which our specialists confirm before recommending treatment.

We want to be honest with you. Immunotherapy is not a guaranteed cure, and any doctor who promises a cure is not being truthful. For some patients, immunotherapy controls the cancer well, shrinks it, or helps when other treatments have not worked. For others, it may not be the right fit. The outcome depends on the type and stage of blood cancer, your age, your overall health and how the disease responds. Some blood cancers are very treatable, while others are harder to control. At CION, we will speak with you openly about what is realistic in your specific case, rather than giving false hope. We walk this journey with you and adjust the plan as your situation changes.

Immunotherapy is generally targeted, but it can still cause side effects. Common ones include fever, chills or a flu-like feeling, especially during the first infusions. Some patients feel tired, develop a rash, or have low blood counts. A more serious concern is an immune reaction, where the boosted immune system also inflames healthy organs such as the lungs, liver or bowel. Some patients also face a higher risk of infection. Most side effects are manageable when caught early, which is why we monitor you closely throughout treatment. If you notice fever, breathlessness, or a severe rash, you should contact your care team straight away. Our doctors will explain the specific risks of your recommended treatment before you start.

Most immunotherapies for blood cancer are given as an infusion through a drip into a vein. Many are delivered as day-care visits, so you can often go home the same day. Some bispecific antibodies need closer observation, especially in the early doses. The schedule varies widely depending on the specific drug and how your cancer responds. Some treatments are given in cycles over several weeks or months, while others continue for longer with regular checks. There is no single answer for everyone. During your 45-minute consultation, your haemato-oncologist will explain the likely schedule for your treatment, what each visit involves, and how we will track your progress, so you can plan around your daily life.

The only way to know is through a proper review by a haemato-oncologist. It starts with confirming the exact type and subtype of your blood cancer, and checking whether your cancer cells carry the marker a given immunotherapy needs. We order only the tests that are necessary, never unnecessary ones. Your case is then discussed at our tumour board, so the recommendation comes from a team rather than a single opinion. After this, we sit with you for a detailed 45-minute consultation and explain your options in plain words, including honest pros and cons. We also share a transparent cost estimate before you decide. You can book a free consultation or a free second opinion with our team at any time.